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Transfer of 1,4-Dihydropyridine Sensitivity
from L-Type to Class A (BI) Calcium Channels
Manfred Grabner, Zhengyi Wang, Steffen Hering, found to contribute to the formation of the DHP receptor
JoÈ rg Striessnig, and Hartmut Glossmann site on the a1S subunit (Nakayama et al., 1991; Striessnig
Institut fuÈ r Biochemische Pharmakologie et al., 1991; Catterall and Striessnig, 1992). These com-
UniversitaÈ t Innsbruck prised parts of the pore-lining S5-S6 linkers (P or SS
Peter Mayrstraûe 1 regions) together with transmembrane segments S6 of
A-6020 Innsbruck repeats III (IIIS6) and IV (IVS6). Together with electro-
Austria physiological studies (Kass and Arena, 1989; Kass et
al., 1991; StruÈ bing et al., 1993), these data provided
evidence that regions close to segment IIIS6 and near
the extracellular pore opening form the core of the DHPSummary
receptor site.
In the first approach with recombinant DNA-tech-L-type Ca21 channels are characterized by their unique
niques to localize regions critical for DHP action, chi-sensitivity to organic Ca21 channel modulators like the
meric a1 constructs were analyzed after functional ex-1,4-dihydropyridines (DHPs). To identify molecular
pression (Tang et al., 1993). The DHP sensitivity of themotifs mediating DHP sensitivity, we transferred this
a1C subunit (Mikami et al., 1989) was lost after specificsensitivity from L-type Ca21 channels to the DHP-
insertions of corresponding parts of a DHP-insensitiveinsensitive class A brain Ca21 channel, BI-2. Expres-
a1A subunit (Mori et al., 1991). In agreement with earliersion of chimeras revealed minimum sequence
results from peptide mapping experiments (Nakayamastretches conferring DHP sensitivity including seg-
et al., 1991; Striessnig et al., 1991; Catterall and Striess-ments IIIS5, IIIS6, and the connecting linker, as well
as the IVS5±IVS6 linker plus segment IVS6. DHP ago- nig, 1992), it was concluded that the C-terminal half
nist and antagonist effects are determined by different of repeat IV of a1C must contain regions necessary for
regions within the repeat IV motif. Sequence regions sensitivity to DHPs. A role of the SS2-S6 region of repeat
responsible for DHP sensitivity comprise only 9.4% of III for DHP action was strongly rejected by Tang et al.
the overall primary structure of a DHP-sensitive a1A/ (1993). However, this conclusion was based on experi-
a1S construct. This chimera fully exhibits the DHP sen- ments in which only a portion of the proposed core
sitivity of channels formed by L-type a1 subunits. In region of the DHP receptor site was replaced by the a1A
addition, it displays the electrophysiological proper- sequence.
ties of a1A, as well as its sensitivity toward the peptide We have now identified in great detail the sequence
toxins v-agatoxin IVA and v-conotoxin MVIIC. stretches within various a1 subunits that confer DHP
drug sensitivity. In contrast to a ``destructive'' approach
(i.e., removal of drug sensitivity via chimeric constructs),Introduction
we favored a ``constructive'' method. Here, we trans-
posed sequence stretches from two distinct classes ofIn excitable cells, intracellular concentrations of free
DHP-sensitive L-type channel a1 subunits, namely fromCa21 are regulated via voltage-dependent Ca21 chan-
rabbit heart a1C (Mikami et al., 1989) and carp (Cyprinusnels. These channels can be distinguished according to
carpio) skeletal muscle a1S (Grabner et al., 1991) intobiophysical and pharmacological criteria into different
the corresponding regions of the DHP-insensitive rabbittypes (L, P, N, R, Q, and T; Birnbaumer et al., 1994;
brain a1A (BI-2) channel (Moriet al., 1991). Chimeric chan-Dunlap et al., 1995). At least three classes of a1 subunits,
nels were studied for DHP agonist and antagonist sensi-encoded by different genes, participate in the formation
tivity after heterologous expression in Xenopus laevisof L-type channels: class S in skeletal muscle; class C
oocytes. Our final goal was to create a DHP agonist±in smooth muscle, cardiac muscle, and neurons; and
and DHP antagonist±sensitive a1 chimeric constructclass D in neuroendocrine cells (reviewed in Hofmann
containing only a minimal quantity of L-type sequenceet al., 1994). They can be discriminated from all other
(``minimum chimera'').Ca21 channel types by their sensitivity to 1,4-dihydropy-
Our results demonstrate that 9.4% of L-type a1 se-ridines (DHPs). These drugs label a high affinity DHP
quence, covering transmembrane segments IIIS5 andreceptor domain located on the channel's a1 subunit
IIIS6, including their connecting linker (pore loop), to-(Catterall et al., 1988; Glossmann and Striessnig, 1990).
gether with a second motif comprising the IVS5-IVS6Some DHPs act as ``Ca21 antagonists'' or channel block-
linker plus transmembrane segment IVS6, are sufficienters (e.g., isradipine, nifedipine, nimodipine), preferen-
to introduce DHP agonist and antagonist sensitivity intotially stabilizing the inactivated state of the channel,
a1A. Biophysical and pharmacological properties of thiswhereas others (e.g., Bay K 8644) are ``Ca21 agonists''
minimum chimera were studied and compared with(channel activators) and promote the open state (Hess,
channels entirely composed of L-type sequence.Subse-1990; Hille, 1992).
quently, we identified distinct regions responsible forTo gain a deeper insight into themolecular mechanism
agonist or antagonist action within these ``minimum mo-of L-type channel modulation by DHPs, attempts were
tifs.'' Delineating the architecture of the DHP-agonistmade to elucidate the structural details of the DHP bind-
and DHP-antagonist interaction sites on the level of indi-ing domain(s). With peptide mapping techniques after
photolabeling, two distant sequence stretches were vidual amino acids now seems possible.
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Results agonist (6)-Bay K 8644 (10 mM) and blocked by (6)-
isradipine (10 mM; Figure 2). As observed with native
L-type channels, Bay K 8644 increased peak IBa; slowedMapping the Sequence Motifs Responsible for DHP
current activation; shifted the peak, as well as the mid-Sensitivity of L-Type a1 Subunits
point voltage of the current activation curve to moreTo determine the regions mediating DHP sensitivity in
negative potentials; and slowed tail currents (Figure 2).L-type calcium channels, we introduced sequence
Current block by the DHP antagonist (6)-isradipine (10stretches from two different DHP-sensitive L-type chan-
mM) was accompanied by an acceleration of currentnel a1 subunits into the DHP-insensitive a1A (Mori et al.,
decay (Figure 2) and a shift of the steady-state inactiva-1991). All chimeras were coexpressed in X. laevis oo-
tion curve toward more negative voltages (data notcytes, together with the b1A subunit. Ca21 channel b
shown). Despite the pronounced differences in currentsubunits are known to enhance channel function (cur-
kinetics between Lh and Ls, similar changes in the volt-rent amplitudes, drug binding) and also to affect current
age-dependence of IBa were induced by Bay K 8644. Thekinetics (Lacerda et al., 1991; Mori et al., 1991; Varadi
observed shift in the voltage dependence of activation toet al., 1991; Wei et al., 1991; Grabner et al., 1994; Mitter-
negative potentials was, however, less pronounced fordorfer et al., 1994). Figure 1A gives a schematic struc-
chimera Ls (Figures 2A and 2B).tural overview and Figure 1B, an overview on the sensi-
The effect of the antagonist isradipine on IBa inactiva-tivity of the resulting chimeras toward DHP agonists and
tion was most prominent for the slowly activating chi-antagonists, respectively. The DHP-sensitive a1 sub-
mera Ls. Under control conditions, current did not reachunits used for chimerization were a1C from rabbit heart
its peak during a 350 ms test pulse (Figure 2B) (see also(Mikami et al., 1989) and a1S from carp skeletal muscle
Wang et al., 1995) but ``inactivated'' in the presence(Grabner et al., 1991). Similar to a1S from rabbit skeletal
of 10 mM (6)-isradipine (Figure 2B). Therefore, thesemuscle (Tanabe et al., 1987), a1S from carp skeletal mus-
isradipine induced changes in current kinetics, espe-cle could not be functionally expressed in Xenopus oo-
cially of the slowly activating chimeras, precluded acytes. However, after replacing repeats I and II of carp
comparison of the drug effects (Figure 1B) by measuringa1S with the corresponding a1C sequences, this construct
inhibition of peak current values. Antagonist effects of(termed Ls in Figure 1A) formed DHP agonist± and DHP
isradipine were therefore evaluated as current inhibitionantagonist±sensitive channels (Figure 1B and Figure 2).
at the end of a 350 ms test pulse to 120 mV. Taking
In contrast, a construct (data not shown) that contained
into account that the agonist effects on IBa were alwaysrepeats I and II from a1C and repeats III and IV from a1A more pronounced in the voltage range from 210 to 0
remained DHP insensitive like a1A. Clearly, repeats I and mV, we assessed DHP agonist effects on IBa as the in-II alone do not determine DHP sensitivity, but repeats
crease in maximum current amplitude during a 350 ms
III and IV of carp a1S supported DHPsensitivity and could test pulse to 210 to 0 mV (Figure 1B).
therefore be for used for chimerization. As previously
Previous work suggested that the pore regions and
described (Wang et al., 1995) the expression of a1C was adjacent transmembrane segments S6 of repeats III and
improved by replacing parts of its N-terminus with carp IV of skeletal muscle a1S play a key role for the formation
a1S sequence. The respective construct is termed Lh. of the DHP receptor site (Nakayama et al., 1991; Striess-
Also, chimera Ls contained the carp a1S N-terminal se- nig et al., 1991; Tang et al., 1993). Consequently, chimera
quence. AL1 (Figure 1A) was constructed where these regions
Figure 2 illustrates electrophysiological properties were replaced in a1A by the corresponding carp a1S
and DHP sensitivity of Lh (Figure 2A), Ls (Figure 2B), L-type sequences. AL1 displayed kinetic properties typi-
and a1A (Figure 2C). Ls activated significantly more cal for a1A (Mori et al., 1991; Sather et al., 1993) but
slowly than the other constructs. A detailed comparison surprisingly was insensitive to 10 mM of the DHP agonist
of the kinetic properties of Lh and Ls has been published (6)-Bay K 8644 or the antagonist (6)-isradipine (Figure
recently (Wang et al., 1995). In contrast to the other 1B). Clearly, additional regions are required to mediate
constructs, Ba21 inward currents (IBa) through a1A DHP sensitivity. As for a1A (see above), replacement of
showed significant inactivation of typically 35%±50% of repeats I and II by a1C sequence in AL2 (Figure 1A) did
the current after a 350 ms test pulse to 110 mV. Inward not support DHP sensitivity (Figure 1B). Therefore, a
currents through a1A were unaffected by 10 mM solutions model is unlikely where all four P regions form a (pseudo)
of (6)-Bay K 8644 and (6)-isradipine (Figure 2C). symmetrical interaction site. DHP-agonist and DHP-an-
tagonist sensitivity could be restored by changing theIBa of chimeras Lh and Ls were stimulated by the DHP
Figure 1. Contribution of Individual Regions of a1 Subunits to DHP Sensitivity
(A) Schematic representation of the DHP-insensitive class A channel (designated: A) and of the chimeric a1 subunits L and AL1±AL15. DHP-
sensitive L-type sequence stretches are indicated by black segments and bold lines. Gray segments and thin lines represent DHP-insensitive
a1A sequences. Arrows indicate the transitions between the different L-type sequence stretches (see Results and Experimental Procedures)
in chimeras Lh and Ls.
(B) Inhibition or stimulation of barium currents (IBa) through chimeric channels expressed in oocytes of X. laevis, elicited by 10 mM solutions
of racemic isradipine and Bay K 8644, respectively. Chimeras AL1±AL15 are indicated by numbers 1±15, respectively. Bars represent the
mean 6 SEM of 4 to 11 experiments in oocytes from at least 2 frogs. Block (current inhibition at the end of a 350 ms test pulse to a test
potential of 120 mV) and stimulation of IBa (increase of maximal current amplitude during a 350 ms depolarization to a test potential 20 mV
negative to the peak potential of the I±V curve) were recorded in 40 mM Ba21 from a holding potential of 280 mV.
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Figure 2. Effects of DHPs on IBa Carried by L-type Chimeras Lh and Ls or by the Class A Channel a1A
(Left column) Families of IBa currents shown for L-type chimeras Lh (A) and Ls (B) and for a1A (C) were recorded in 10 mV increments at test
potentials ranging from 230 to 120 mV from a holding potential of 280 mV. Currents had threshold potentials in the range of 240 to 220
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region from segment IIIS1 through IIIS5 of AL2 from not agonist-) sensitive chimera AL13 demonstrates that
L-type sequence is required only within a fraction of theclass A to L-type sequence yielding chimera AL3 (Fig-
IVS5-IVS6 linker to mediate antagonist sensitivity. Theseure 1). This suggested an essential role of IIIS1-IIIS5 (or
results extend the findings of Tang et al. (1993), as weat least parts of it) for DHP action. Moreover, restoration
can show that in repeat IV only sequence differencesof DHP sensitivity in chimera AL3 also indicated that
within IVS6 account for agonist sensitivity, whereas thethe carboxy-terminal tail of the a1 subunit has no essen-
N-terminal half of the IVS5-IVS6 linker of carp a1S contrib-tial role in the formation of the DHP binding pocket.
utes also to DHP antagonist sensitivity.After replacement of the IVS5-IVS6 linker plus seg-
To further refine the role of repeat III, we swappedment IVS6 of AL3 by class A sequence to create chimera
segment IIIS6 from L-type to class A sequence (chimeraAL4, the DHP agonist and antagonist sensitivity was
AL11). This eliminated DHP antagonist and agonist sen-removed (Figure 1B), which in accordance with the re-
sitivity. Tang et al. (1993) replaced the first 9 amino acidssults of previous peptide mapping and chimeric deletion
of transmembranesegment IIIS6 in a1C with a1A sequencestudies (Nakayama et al., 1991; Striessnig et al., 1991;
without detectable effect on DHP sensitivity (their chi-Tang et al., 1993) confirms that this part of repeat IV is
mera CBC3). As we completely replaced IIIS6, the aminoan essential element for DHP interaction.
acids responsible for DHPsensitivity have to begroupedIn chimera AL5, repeat II, the I-II linker, and the
between residues in positions 10±25 in IIIS6 of the corre-C-terminal half of IS6 of chimera AL3 were replaced by
sponding a1C sequence. All of the remaining intracellulara1A sequence (Figure 1A). As DHP sensitivity was fully
sequences could be removed from chimera AL9 withoutpreserved in AL5 (Figure 1B), the sequence divergence
loss of DHP sensitivity resulting inour minimum chimera,between L-type and class A channels within this region
AL12s. The sensitivity of AL12 chimeras to (6)-Bay Kdoes not account for the differences in DHP sensitivity.
8644 and (6)-isradipine was preserved, irrespective ofUnfortunately, at this point we were unable to test the
the source of L-type sequence used (a1C, a1S; yieldingimportance of repeat I, as the expression of chimeras
AL12h and AL12s, respectively; Figures 1A and 1B). Fur-composed of repeat I from a1A and repeat III from a1S ther replacement of L-type sequence within the P regiondid not yield functional channels. This result was ob-
as well as S6 in repeat III (see chimeras AL14 and AL15)
tained with several independent polymerase chain reac-
yielded DHP agonist± and DHP antagonist±insensitive
tion (PCR) products. It could not be explained by PCR-
channels (Figure 1), demonstrating the importance
induced changes in the DNA sequence as confirmed by
of these regions for the formation of the DHP interac-
DNA sequencing of PCR-generated repeat I cDNAs.
tion site.
As a next step, we further reduced the amount of
L-type sequence of repeat III starting from chimera AL5. Properties of the Minimal Chimera AL12s
Evidence for an important role of segments IIIS5 and
Of the AL12 construct sequences, 90% comprise a1AIIIS6 and the IIIS5-IIIS6 linker was demonstrated by the sequence. The current kinetics of the studied chimeras
loss of DHP sensitivity in AL6, where the stretch from closely resemble those of a1A (Figure 1A and Figure 3);
IIIS5-IIIS6 was switched to class A sequence. Because but, in contrast, the currents are sensitive to DHPs as
L-type sequence only within the P region and S6 in exemplified for AL12s in Figures3A±3F. Current increase
repeat III, but excluding IIIS5, was not sufficient to create by (6)-Bay K 8644 (Figure 3A) or by DHP agonist (1)-
DHP sensitivity in chimeras AL1 and AL2, the results with 202±791 (Figure 3E) is associated with the typical shifts
AL6 suggest the importance of IIIS5. By constructing in the maximum of the I±V curves toward more negative
further chimeras (AL7 and AL8), we could exclude the potentials and similar changes in current kinetics as
following sequence stretches as contributing to DHP found for chimeras Lh and Ls (see Figure 2). Current
site formation: the cytoplasmic linker between repeats inhibition by isradipine was concentration dependent
II and III, the region from segments IIIS1 to IIIS2 (chimera and stereoselective (Figures 3C and 3D) and occurred
AL7), and the region from IIIS3 to IIIS4 (chimera AL8). with similar apparent potency as block of currents medi-
After L-type sequences in repeat III were significantly ated by a1C (Figure 3D). We found no evidence for major
reduced in chimera AL8, the swapping of repeat I from differences in DHP sensitivity between AL12s and a1C
L-type to class A sequence was tolerated, yielding chi- (Figure 3D).
mera AL9, which formed DHP-sensitive channels. AL9 FPL 64176 is a novel benzoyl pyrrole L-type channel
was then further modified to refine the roles of trans- agonist structurally unrelated to DHPs. Radioligand
membrane segments IVS6 and IIIS6 and of the remaining binding studies indicate (Kunze and Rampe, 1992; Ginap
cytoplasmic sequences. Changing segments IVS6 of et al., 1993) that FPL 64176 labels a site distinct from
AL9 into class A sequence (chimera AL10) resulted in DHPs. Interestingly, FPL 64176 sensitivity is absent in
the complete loss of sensitivity for the DHP agonist a1A (data not shown; but see Sather et al., 1993) but
Bay K 8644, whereas the sensitivity for the antagonist was introduced into chimera AL12s (Figure 3G). This
suggests that critical determinants of the FPL 64176isradipine was retained. Similarly the antagonist- (but
mV and reached peak current values between 0 and 120 mV. One typical recording out of at least seven experiments is shown.
(Middle column) IBa recorded from the same oocytes 2±3 min after perfusion with solutions containing 10 mM of agonist (6)-Bay K 8644 or of
antagonist (6)-isradipine.
(Right column) Corresponding current±voltage relations of maximum inward IBa obtained during 350 ms voltage steps before (squares) and
after (circles) the application of DHPs. The holding potential was 280 mV, and test potentials ranged from 260 to 150 mV. The range of
current stimulation by (6)-Bay K 8644 was as follows: Lh: 2.7- to 6.3-fold (n 5 5); Ls: 1.7- to 7.5-fold (n 5 7).
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Figure 3. Electrophysiological and Pharmacological Properties of Chimera AL12s
In each panel typical recordings out of at least three experiments are shown.
(A and B) Families of currents recorded in 40 mM Ba21 at test potentials from 230 to 110 mV from a holding potential of 280 mV are shown
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Figure 4. Sensitivity of Chimera AL12s to the Funnel Web Spider Toxin v-Agatoxin-IVA
Experiments were carried out in 2 mM Ba21 (low Ba21 solution; test potential: 210 mV; holding potential: 280 mV). After recording the control
IBa, oocytes were superfused with 1 mM of toxin-containing solution. After steady-state inhibition of IBa by the toxin had occurred (between 3
to 4 min), (6)-Bay K 8644 was added to 10 mM. Agonist-stimulated IBa was recorded 1 min after drug application. One out of three experiments
yielding similar results is shown for Lh (A), a1A (B), and AL12s (C).
and DHP binding domain are located in close vicinity stretches required for transfer of DHP sensitivity were
associated exclusively with repeats III and IV. The DHPwithin the a1 subunit.
agonist± and DHP antagonist±sensitive chimeras with
minimum L-type sequence portions contained L-typeNeurotoxin Sensitivity of Chimera AL12s
Class A a1 subunits expressed in Xenopus oocytes give sequences of either a1C or carp a1S in transmembrane
segments IIIS5, IIIS6, and IVS6, as well as in the S5-S6rise to Q-type currents, similar to those recently de-
scribed in hippocampal pyramidal and cerebellar gran- linkers in repeats III and IV. Combining results of the
present work with previous data (Tang et al., 1993) leadsule neurons (Wheeler et al., 1994; Randall and Tsien,
1995). Q-type currents in Xenopus oocytes are blocked to a model of minimal L-type sequence requirements
for the formation of the DHP binding pocket as depictedby the spider toxin v-Agatoxin IVA (v-Aga IVA; IC50 5
200±1000 nM; Sather et al., 1993; Stea et al., 1994) and in Figures 5A and 5B. According to a molecular model
of voltage gated cation channels (Guy and Conti, 1990)by the marine snail toxin v-conotoxin MVIIC (v-CTx
MVIIC; IC50 . 100 nM; Sather et al., 1993). Introduction these sequence stretches are believed to participate
directly in the formation of the ion conducting pathwayof L-type sequence into a1A (chimera AL12s) did not
affect the sensitivity to these toxins. Block of AL12s by or to be located close to the extracellular pore opening
(Figure 5C). A further reduction of L-type sequence inthe two toxins was similar to the block observed for a1A
and is exemplified for v-Aga-IVA in Figures 4B and 4C. repeat III resulted in a loss of DHP effects, suggesting
that structural determinants for both DHP agonist andAs expected (Sather et al., 1993), a1C (expressed as Lh)
was toxin insensitive (Figure 4A). Similar to the v-cono- antagonist interaction reside close to pore-forming re-
gions in repeat III. The second DHP interaction sitetoxin GVIA block of N-type channels (Ellinor et al., 1994),
these peptide toxins most likely interact with thechannel formed by residues in repeat IV is able to discriminate
between channel activators and blockers: critical deter-at the outer entrance of the ionic pore. We therefore
consider the two pore-forming linkers of a1A, which were minants for DHP agonists are located within transmem-
brane segment IVS6 of L-type channels, whereasreplaced by L-type sequences in AL12s to create the
DHP sensitivity, as insignificant for toxin interaction. L-type-channel-specific residues support DHP antago-
nist action within the N-terminal half of the IVS5-IVS6
linker. Functional studies have provided evidence forDiscussion
distinct DHP agonist and antagonist interaction sites
(Kamp et al., 1989; Lacerda and Brown, 1989; Hughesa1 Subunit Regions Responsible for
DHP Sensitivity et al., 1990). DHPs induce a variety of changes in Ca21
channel gating and different channel state models haveBy generating a variety of chimeric a1 constructs be-
tween DHP-sensitive and DHP-insensitive a1 subunits, been proposed to explain kinetic effects on single chan-
nel and whole cell Ca21 channel currents (Bean, 1984;we succeeded in introducing DHP sensitivity into the
a priori DHP-insensitive a1A subunit. L-type sequence Hess et al., 1984; Sanguinetti et al., 1986; Hering et al.,
before (left panel) and after (middle panel) application of 10 mM (6)-Bay K 8644 (A) or (6)-isradipine (B). The corresponding current±voltage
relation curves (peak IBa) before (squares) and during (circles) drug application are shown at right.
(C) Stereoselective inhibition of IBa through chimera AL12s 3±4 min after perfusion with 1 mM (1)- and (-)-isradipine-containing solutions.
(D) Concentration±response curves of (1)-isradipine (closed circles) and (2)-isradipine (open circles) for inhibition of peak IBa carried by chimera
AL12s, compared with the effects of (6)-isradipine on L-type chimera Lh (open squares). Data from three recordings were pooled and are
given as means (SEM , 20%). IC50 values were calculated by fitting the experimental data to the general-dose-response equation (slope
factor 5 1; De Lean et al., 1978): Lh ([6]-isradipine): IC50 5 1.6 mM; AL12s ([1]-isradipine): IC50 5 910 nM; AL12s ([2]-isradipine): IC50 5 45 mM.
(E±G) Sensitivity of chimera AL12s to 10 mM solutions of the DHP agonist (1)-S202±791 (E), the DHP antagonist (2)S202±791 (F), and the
non-DHP agonist FPL 64176 (G). (E)±(G) show representative current traces recorded during depolarization to a test potential of 110 mV from
a holding potential of 280 mV.
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Figure 5. Proposed Minimum L-type Se-
quence Stretches Required for Making Class
A Channel a1A DHP Sensitive
Membrane folding model of the a1 subunit
depicting minimum L-type sequence require-
ments in DHP-insensitive class A channels
for providing DHP-agonist (Bay K 8644) (A)
and DHP-antagonist (isradipine) (B) sensitiv-
ity. Black segments and bold lines represent
DHP-sensitive L-type sequence stretches;
gray segments and thin lines, DHP-insensi-
tive a1A sequence stretches. As repeats I and
II are entirely composed of a1A sequence, only
repeats III and IV are illustrated in (A) and (B).
(C) Top view model of the a1 subunit ac-
cording to proposed molecular models (Guy
and Conti, 1990). Circles symbolize trans-
membrane segments IS1±IVS6. Black circles
and bold lines represent L-type channel se-
quences; gray circles and thin lines, class A.
Proposed DHP agonist Bay K 8644 (``BAY'')
interaction with structural elements of the a1
subunit inside the channel pore is indicated
by dotted lines and arrows.
1989; Lacerda and Brown, 1989; Marks and Jones, 1992; pocket seems not to interfere with the toxin interaction
site(s). However, we cannot rule out slight changes inBechem and Hoffmann, 1993). The contribution of dis-
tant portions of primary structure for the formation of a the DHP affinity of the recombinant DHP receptor site
in our AL12 chimeras unresolved by functional expres-drug binding site may facilitate ``allosteric'' effects on
L-type channel function, promoting closed (antagonist) sion in Xenopus oocytes. Fourth, by constructing chime-
ras Ls and AL12s, we provide evidence that the pre-or open (agonist) channel conformations. Such allosteric
effects may be most easily exerted by interaction at the viously cloned a1 subunit from carp (Cyprinus carpio)
skeletal muscle belongs to the DHP-sensitive family ofinterface of protein subunits, as has been shown for
allosteric enzymes (Sprang et al., 1987; Georgiadis et a1 subunitsÐsomething that had not been directly sup-
ported by functional expression studies.al., 1992). As the homologous repeats I±IV of the a1
subunit can be regarded as individual channel subunits We conclude that the most important structural deter-
minants for DHP sensitivity reside within the transposedconnected by cytoplasmic loops, DHP binding involving
repeats III and IV may promote conformational changes L-type sequence stretches of chimeras AL12. However,
we cannot completely exclude the possibility that, whenof tertiary structure more efficiently than by interaction
within only one repeat. It is, however, interesting to note bound to the channel with high affinity, the DHP mole-
cule interacts with additional amino acids outside thesethat the typical changes in current kinetics produced by
agonist and antagonist DHPs require structural ele- regions that are also provided by the a1A primary struc-
ture. For several reasons the identification of such resi-ments that are localized in channel repeats III and IV,
whereas molecular determinants for activation and inac- dues will be difficult. One possible approach consists
in the construction of chimeras analogous to AL12 buttivation have been localized in repeat I of the a1 subunit
(Tanabe et al., 1991; Nakai et al., 1994; Zhang et al., using a different DHP-insensitive a1 subunit (e.g., a1B) as
a host sequence. The high sequence homology among1994; but see Wang et al., 1995).
In the present work, we extend previous findings con- non-L-type a1 subunits is the main drawback for this
approach. Alternatively, alanine scanning mutagenesiscerning the localization of the DHP receptor domain
obtained with antibody mapping (Nakayama et al., 1991; (Ragsdale et al., 1994)canbe carried out but would require
systematic mutation of a large number of residues.Striessnig et al., 1991) or chimeric constructs (Tang et
al., 1993). First, our data provideÐby a constructive
chimeric approachÐdirect evidence for the involvement
of residues within repeat III for DHP agonist and antago- Repeat III Participates in the Formation of the DHP
Binding Pocketnist sensitivity. Second, we directly demonstrate that
portions of the IVS5-IVS6 linker mediate DHP antagonist Closer inspection of the sequence within the regions
conferring DHP sensitivity to AL12 chimeras (Figure 6)sensitivity. Third, our results show that receptors not
only for peptide toxins (Gross et al., 1994) but also for revealed an overall sequence identity of 62% between
a1C and carp a1S. The amino acid identities between thesesmall nonpeptidergic drugs can be successfully trans-
ferred between related ion channels. Obviously, the re- a1 subunits and a1A were 46% and 41%, respectively.
A sequence alignment of the respective sequences ismaining z90% of a1A sequence of AL12s induces no
steric distortion to the overall folding structure of a ste- depicted in Figure 6. All amino acid residues within the
a1A sequence that were not conserved in one of bothreoselective DHP binding pocket. On the other hand,
because the a1A-specific sensitivity for peptide toxins DHP-sensitive a1 subunits used in our study are high-
lighted. Among those, asterisks indicate residues thatwas not impaired, the introduction of the DHP binding
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Figure 6. Partial Sequence Alignment of a1C and Carp a1S with the Corresponding a1A Sequences
Amino acid alignment of sequence stretches of a1C and carp a1S of repeat III (A) and repeat IV (B) able to transfer DHP sensitivity into class
A channels after replacing the aligned a1A sequences (chimeras AL12). Transmembrane segments and intramembrane SS1-SS2 regions are
indicated by cylinders. Numbers of amino acid positions correspond to a1C (Mikami et al., 1989). Marked sequence stretches CBC3 and CBC7
refer to the chimeric constructs analyzed by Tang et al. (1993). Arrows mark transitions between L-type and class A sequence of the constructs
indicated above the arrows (see also Figure 1A). Residues within the a1A sequence not found in one of either DHP-sensitive a1 subunits studied
are highlighted. Asterisks indicate residues identical within all L-type and also identical within all ``non-L-type'' channels cloned so far, but
different between L-type and non-L-type channels.
were identical within all L-type channels and also identi- amino acids must reside between positions 1414 and
1450 (a1C). This region includes a highly acidic 8 aminocal within all ``non-L-type'' channels cloned so far, but
that were heterologous comparing L-type with non-L- acid residue insert in a1A, as well as 17 residues heterolo-
gous to our DHP-sensitive subunits.type channels. These residues are clustered especially
within transmembrane segments IIIS5 and IIIS6 and are Additional residues between positions 1454 and 1498
(a1C numbering) are essential to create agonist (Bay Kmajor candidates for further mutational analyses. From
the DHP insensitivity of chimeras AL1, AL2, AL6, AL11, 8644) sensitivity. Concerning transmembrane segment
IVS6, agonist sensitivity is restricted to 7 amino acidAL14, and AL15, we conclude that residues in IIIS5, in
the IIIS5-IIIS6 linker, and in IIIS6 are required for forming differences. As DHP agonists are believed to open the
the DHP interaction site in repeat III. As previously channel via formation of a hydrogen bond (Triggle et al.,
shown, the sequence stretch between SS2 in repeat III 1991), we consider tyrosine (1490) as the most likely
and the N-terminal portion of IIIS6 (Figure 6) (chimera interaction site (Figure 6).
CBC3 by Tang et al., 1993) can be replaced by a1A se- The L-type sequence stretches important for DHP
quence without effect on DHP agonist and antagonist sensitivity (as outlined in Figure 5) include all regions
sensitivity. Therefore, amino acids determining DHP that have been previously identified as parts of the DHP
sensitivity in repeat III must be located between posi- receptor domain of purified rabbit skeletal muscle a1
tions 1063±1144 and 1180±1197 (numbers refer to a1C; subunits by photoaffinity labeling and antibody mapping
Mikami et al., 1989). (Nakayama et al., 1991; Striessnig et al., 1991). The im-
portance of IIIS6 and the IIIS5-IIIS6 linker has been pre-
dicted from these studies. Moreover, photolabeling withDifferential Interaction of DHP Agonists and
the DHP antagonist (1)-[3H]isradipine also predicted theAntagonists Within Repeat IV
minor importance of IVS6 for DHP antagonist interac-In repeat IV, residues important for DHP agonist and
tion, a finding confirmed by our results. In contrast toantagonist action can be predicted more precisely. The
an interpretation of a preliminary study (Tang et al.,sequence stretch supporting DHP antagonist sensitivity
1993), we consider antibody mapping analysis of photo-in chimera AL13 is indicated (Figures 1A, 5B, and 6).
labeled regions a very valuable tool to predict the posi-Accordingly, a1C containing a1A sequence in chimera
tions of drug receptor sites within ion channel proteins.CBC7 (see Figure 6) reported by Tang et al. (1993) sup-
ported DHP antagonist sensitivity. Thus, the crucial Mutational studies will mainly allow delineation of amino
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coligated with SalI-BamHI fragment of AL2 (3317S-39 polylinker) intoacid residues involved in the binding of critical pharma-
KpnI/BamHI polylinker sites of transcription plasmid pNKS2.cophores of drugs. Antibody mapping of photolabeled
AL4regions should also yield information about the localiza- S(1±60), H(145±920), S(806±1104), A(1544±2424). ClaI*-SphI frag-
tion of drug±protein interaction sites that contribute only ment of A (4925±5862) was coligated with an SphI-SpeI fragment
weakly to binding affinity.Therefore, they providehelpful of AL3 (5862A-39 polylinker) into the ClaI* (4925A) and SpeI (39 poly-
linker) sites of AL3.information about more peripheral portions of the DHP
AL5binding pocket and, thus, about the tertiary structure of
S(1±60), H(145±422), A(348±724), H(794±920), S(806±1104), A(1544±
a1 subunits. 1723), S(1311±1437), A(1856±2424). BamHI*-SpeI* fragment of A
Together, our data substantially restrict the regions (1333±2464) was coligated with SpeI*-ClaI* fragment of AL3 (2569H-
important for DHP interaction within L-type Ca21 channel 3498S) into the BamHI (1456H) and ClaI* (4925A) sites of AL3 after
deletion of the BamHI site in the 39 polylinker.a1 subunits. They pave the way for an even more detailed
AL6analysis of the DHP binding domain on the level of indi-
S(1±60), H(145±422), A(348±724), H(794±920), S(806±1034), A(1377±vidual amino acid residues.
1723), S(1311±1437), A(1856±2424). SpeI*-SalI* fragment of AL5
(2569H-2984S) was coligated with the SalI*-ClaI* fragment of A
(4420±4925) into the SpeI* (2464A) and ClaI* (4925A) sites of AL5.
Experimental Procedures AL7
S(1±60), H(145±422), A(348±1309), S(872±1104), A(1544±1723),
Construction of Chimeric a1 cDNAs S(1311±1437), A(1856±2424). XhoI-ApaI fragment of A (1689±3949)
L-type a1 chimeras L(h/s) and class A/L-type chimeras AL1- was coligated with the ligation product from the ApaI-NarI* fragment
AL12(h/s) and AL13-AL15 (see Figure 1A) between the DHP-insensi- of A (3949±4220) plus the NarI*-SalI fragment of S (2796±3317) into
tive rabbit brain class A Ca21channel (BI-2) a1A (A; Mori et al., 1991) the XhoI (1689A) and SalI (3317S) sites of AL5.
and the DHP-sensitive L-type channels from carp skeletal muscle AL8
a1S (S; Grabner et al., 1991) and rabbit heart a1C-a (H; Mikami et al., S(1±60), H(145±422), A(348±1369), S(928±1104), A(1544±1723),
1989) were constructed and inserted into polyadenylating transcrip- S(1311±1437), A(1856±2424). NheI-ClaI* fragment (3543A-3498S)
tion plasmids pNKS2 (a gift of O. Pongs) or pSPCBI-2 (Mori et al., was generated by gene SOEing (overlap: 4400A/2965S) and was
1991) as follows. inserted into the NheI (3543A) and ClaI* (4925A) sites of AL7.
Lh AL9
A(1±1369), S(928±1104), A(1544±1723), S(1311±1437), A(1856±2424).Numbers in parentheses are amino acid numbers here and below,
HindIII-XhoI fragment of A in plasmid pSPCBI-2 (59 polylinker-1679)respectively: S(1±60), H(145±2171). The KpnI-AccIII fragment of H
was coligated with the XhoI-NheI fragment of A (1679±3543) into(59 polylinker-620) (nucleotide numbers in parentheses here and
the HindIII (59 polylinker) and NheI (3543A) sites of AL8.below, respectively) was replaced by a KpnI-AccIII fragment of S
AL10(59 polylinker-360) using a common AccIII restriction site of a KpnI-
A(1±1369), S(928±1104), A(1544±1723), S(1311±1376), A(1795±2424).BamHI (59 polylinker-1456) H subclone in pBluescript SK1 (Stra-
ClaI*-XbaI* fragment of AL9 (4925A-4307S) was coligated with thetagene). This modification of the 59 region leads to higher expression
SpeI*-BglII fragment of A (5671±6185) into the ClaI* (3498S) andlevels compared with unmodified a1C-a cDNA and was therefore rou-
BglII (6185A) sites of AL9.tinely used in our expression studies (Mitterdorfer et al., 1994, 1995;
AL11Wang et al., 1995).
A(1±1369), S(928±1046), A(1486±1723), S(1311±1376), A(1795±2424).To construct the following a1 chimeras (as depicted in Figure 1A),
SalI*-ClaI* fragment of A (4744±4925) was inserted into the SalIPCR was used to create either common or compatible (SalI-XhoI;
(3317S) and ClaI* (4925A) sites of AL10.NsiI-PstI; XbaI-SpeI; HpaI-PvuII-EcoRV) restriction sites by intro-
AL12sducing silent mutations (mutational sites indicated by an asterisk)
A(1±1388), S(947±1082), A(1522±1723), S(1311±1402), A(1821±2424).or vast overlaps in using the ``gene SOEing'' technique (Horton et
The ligation product from the NheI-HpaI* fragment of A (3543±4464)al., 1989). cDNA amplification by PCR (Thermocycler 60, Bio-Med)
plus the PvuII*-SalI fragment of S (3028±3317) was coligated withwas performed with 35 cycles at low stringency (1 min at 948C,
the ligation product from the SalI-HpaI* fragment of S (3317±3424)30 s at 428C, 1.5 min at 728C) using proofreading Pfu-polymerase
plus the EcoRV*-ClaI* fragment of A (4851±4925) into the NheI(Stratagene).
(3543A) and ClaI* (4925A) sites of AL9. This intermediate clone wasLs
modified by the following step: ClaI*-SpeI* fragment of AL9 (4925A-S(1±60), H(145±920), S(806±1852). This chimera was assembled by
4409S) was coligated with the XbaI*-BglII fragment of A (5773±6185)ligating the BamHI-HindIII* fragment of H (1456±2953) together with
into the ClaI* (4925A) and BglII (6185A) sites of the intermediatea HindIII-XhoI fragment of S (2600±39 polylinker) into the BamHI
clone.
(1456H) and XhoI (6923H) sites of Lh.
AL12h
Chimeric constructs AL1-AL15 weregenerated using carp skeletal A(1±1388), H(1062±1197), A(1522±1723), H(1413±1506), A(1821±
muscle a1S due to the more favorable location of (putative) restriction 2424). The ligation product from the NheI-HpaI* fragment of A (3543±
enzyme cleavage sites as compared with a1C. 4464) plus theEcoRV*-BglII fragment of H (3381±3704) was coligated
AL1 with the ligation product from the BglII-HpaI* fragment of H (3704±
A(1±1406), S(965±1104), A(1544±1723), S(1311±1437), A(1856±2424). 3777) plus the EcoRV*-ClaI* fragment of A (4851±4925) into the NheI
The ligation product from the NheI-PvuII fragment of A (3543±4512) (3543A) and ClaI* (4925A) sites of AL9. The resulting intermediate
plus the PvuII*-ClaI* fragment of S (3076±3498) was coligated with clone was modified as follows: ligation product from the ClaI*-Nsi*
the ligation product from the ClaI*-NsiI* fragment of A (4925±5456) fragment of A (4925±5456) plus the PstI*-SpeI* fragment of H (4421±
plus the PstI*-SphI* fragment of S (4107±4498) into the NheI (3543A) 4729) was coligated with XbaI*-SphI* fragment of A (5773±5862) into
and SphI (5862A) sites of plasmid pSPCBI-2 after polylinker re- the ClaI* (4925A) and SphI (5862A) sites of the intermediate clone.
duction. AL13
AL2 S(1±60), H(145±422), A(348±724), H(794±920), S(806±1104), A(1544±
S(1±60), H(145±920), A(1244±1406), S(965±1104), A(1544±1723), 1723), S(1311±1352), A(1774±2424). ClaI*-NsiI* fragment of AL1
S(1311±1437), A(1856±2424). HindIII*-PvuII fragment of AL1 (4024A- (4925A-4244S) was coligated with the Nsi*-BglII fragment of A (5617±
4512A) was ligated together with PvuII*-BamHI fragment (partial 6185) into the ClaI* (3498S) and BglII (6185A) sites of AL5.
cut) of AL1 (3076S-7615A) into the HindIII (2600S) and BamHI (39 AL14
polylinker) sites (partial cut) of chimera Ls. A(1±1369), S(928±967), A(1409±1483), S(1045±1104), A(1544±1723),
AL3 S(1311±1437), A(1856±2424). NheI-PvuII* fragment of AL9 (3543A-
S(1±60), H(145±920), S(806±1104), A(1544±1723), S(1311±1437), 3076S) was coligated with the PvuII-SalI* fragment of A (4512±4744)
into the NheI (3543A) and SalI (3317S) sites of AL9.A(1856±2424). KpnI-SalI fragment of Ls (59 polylinker-3317S) was
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AL15 Bechem, M., and Hoffmann, H. (1993). The molecular-mode of action
A(1±1369), S(928±1046), A(1486±1723), S(1311±1437), A(1856±2424). of the Ca21 agonist (2)-Bay K 8644 on the cardiac Ca21 channel.
SalI*-ClaI* fragment of chimera AL11 (4744A-4925A) was inserted PfluÈ gers Arch. 424, 343±353.
into the SalI (3317S) and ClaI* (4925A) sites of AL9. Birnbaumer, L., Campbell, K.P., Catterall, W.A., Harpold, M.M., Hof-
Chimeric constructs were verified by extensive restriction enzyme mann, F., Horne, W.A., Mori, Y., Schwartz, A., Snutch, T.P., Tanabe,
mapping, by using at least two independent clones or by confirming T., and Tsien, R.W. (1994). The naming of voltage-gated calcium
their nucleotide composition by cDNA sequencing with the dideoxy channels. Neuron 13, 505±506.
chain termination method (Sanger et al., 1977).
Catterall, W.A., and Striessnig, J. (1992). Receptor sites for calcium
antagonists. Trends Pharmacol. Sci. 13, 256±262.Expression of a1 Chimeras in X. laevis Oocytes
Cappedrun-off poly(A)1 cRNA transcripts from XbaI linearized cDNA Catterall, W.A., Seagar, M.J., and Takahashi, M. (1988). Molecular
templates were synthesized (Krieg and Melton, 1984) and injected properties of dihydropyridine-sensitive calcium channels in skeletal
(15 ng/50 nl) into X. laevis oocytes (stage V-VI) together with approxi- muscle. J. Biol. Chem. 263, 3535±3538.
mately equimolar ratios of b1a subunit cRNA (5 ng/50 nl; Ruth et al., De Lean, A., Munson, P.J., and Rodbard, D. (1978). Simultaneous
1989). analysis of families of simoid curves: application to bioassays, ra-
Two-microelectrode voltage-clamp recordings were carried out
dioligand assay and physiological dose±response curves. Am. J.
2±5 days after injection and incubation of the oocytes at 198C (Meth-
Physiol. 4, 97±102.fessel et al., 1986). Oocytes were prepared as previously described
Dunlap, K., Luebke, J.I., and Turner, T.J. (1995). Exocytotic Ca21(Wang et al., 1995) and were analyzed for the presence of Ba21
channels inmammalian central neurons. Trends Neurosci. 18,89±98.inward currents (IBa) through voltage-dependent Ca21 channels using
the conventional two microelectrode voltage-clamp technique Ellinor, P.T., Zhang, J.F., Horne, W.A., and Tsien, R.W. (1994). Struc-
(Turbo Tec 01C, NPI-Electronic, Germany). Voltage recording micro- tural determinants of the blockade of N-type calcium channels by
electrodes and current injecting electrodes were filled with 2.8 M a peptide neurotoxin. Nature 372, 272±275.
CsCl, 0.2 M CsOH, 10 mM EGTA, 10 mM HEPES (pH 7.4) and had
Ellis, S.B., Williams, M.E., Ways, N.R., Brenner, R., Sharp, A.H.,resistances of 0.3±1 MV. All experiments were carried out at room
Leung, A.T., Campbell, K.P., McKenna, E., Koch, W.J., Hui, A., ettemperature using Ba21 as the charge carrier in solutions composed
al. (1988). Sequence and expression of mRNAs encoding the a1of 40 mM Ba(OH)2 or 2 mM Ba(OH)2 (``high barium'' and ``low barium''
and a2 subunits of a DHP-sensitive calcium channel. Science 241,solution, respectively), 40 mM N-methyl-D-glucamine, 10 mM
1661±1664.HEPES, and 10 mM glucose (pH adjusted to 7.4 with methanesul-
fonic acid). The recording chamber with a volume of 150 ml was Georgiadis, M.M., Komiya, H., Chakrabarti, P., Woo, D., Kornuc, J.J.,
continuously perfused with a flow rate of 1 ml/min; drug-containing and Rees, D.C. (1992). Crystallographic structure of the nitrogenase
solutions were applied with identical flow rate. Leakage current iron protein from Azotobacter vinelandii. Science 257, 1653±1659.
correction was performed either by subtracting the Cd21-sensitive Ginap, T., Dooley, D.J., and Feuerstein, T.J. (1993). The non-dihydro-
current (10 mM Cd21 added) or, digitally, by using average values pyridine L-type voltage-sensitive calcium channel activator FPL
of scaled leakage currents elicited by hyperpolarizing voltage pulses 64176 enhances K1-evoked efflux of [3H]norepinephrine from rat
(P/6 protocol). The pClamp software package (vers. 5.51; Axon In- neocortical slices. Neurosci. Lett. 156, 35±38.
struments, Inc.) was used for data acquisition and analysis. Data
Glossman, H., and Striessnig, J. (1990). Molecular properties of cal-were filtered at 1 kHz, digitized at 0.2 kHz, and stored on a computer
cium channels. Rev. Physiol. Biochem. 114, 1±105.hard disk.
Experiments with peptide toxins v-Aga-IVA and v-CTx-MVIIC Grabner, M., Friedrich, K., Knaus, H.G., Striessnig, J., Scheffauer,
were performed in low barium solutions as described (Sather et al., F., Staudinger, R., Koch, W.J., Schwartz, A., and Glossmann, H.
1993). To ensure maximum expression of IBa under these experimen- (1991). Calcium channels from Cyprinus carpio skeletal muscle.
tal conditions, a2/d subunit cRNA (10 ng/50 nl; Ellis et al., 1988) Proc. Natl. Acad. Sci. USA 88, 727±731.
was coinjected. v-Aga-IVA was obtained from BioTrend (Cologne,
Grabner, M., Wang, Z., Mitterdorfer, J., Rosenthal, F., Charnet, P.,Germany); synthetic v-CTx-MVIIC, from Saxon Biochemicals (Han-
Savchenko, A., Hering, S., Ren, D., Hall, L.M., and Glossmann, H.nover, Germany). Toxins were added from 0.1 or 1 mM stock solu-
(1994). Cloning and functional expression of a neuronal calciumtions in distilled water. Unless stated otherwise, holding potential
channel b subunit from house fly (Musca domestica). J. Biol. Chem.was 280 mV, and test potentials were applied to the peak of the
269, 23668±23674.I±V curve.
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